Zhihua Zhu

Dr. Zhihua Zhu


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2021 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YZYing Zhu
Ying Zhu
WYWang Yao
Wang Yao
BXBing-Chen Xu
Bing-Chen Xu
YLYi-Yan Lei
Yi-Yan Lei
QGQi-Kun Guo
Qi-Kun Guo
ZZZhihua Zhu
Zhihua Zhu
Objectives: To develop and validate a radiomics model for evaluating treatment response to immune-checkpoint inhibitor plus chemotherapy (ICI + CT) in patients with advanced esophageal squamous cell carcinoma (ESCC). Methods: A total of 64 patients with advance ESCC receiving first-line ICI + CT at two centers between January 2019 and June 2020 were enrolled in this study. Both 2D ROIs and 3D ROIs were segmented. ComBat correction was applied to minimize the potential bias on the results due to different scan protocols. A total of 788 features were extracted and radiomics models were built on corrected/uncorrected 2D and 3D features by using 5-fold cross-validation. The performance of the radiomics models was assessed by its discrimination, calibration and clinical usefulness with independent validation. Results: Five features and support vector machine algorithm were selected to build the 2D uncorrected, 2D corrected, 3D uncorrected and 3D corrected radiomics models. The 2D radiomics models significantly outperformed the 3D radiomics models in both primary and validation cohorts. When ComBat correction was used, the performance of 2D models was better (p = 0.0059) in the training cohort, and significantly better (p < 0.0001) in the validation cohort. The 2D corrected radiomics model yielded the optimal performance and was used to build the nomogram. The calibration curve of the radiomics model demonstrated good agreement between prediction and observation and the decision curve analysis confirmed the clinical utility. Conclusions: The easy-to-use 2D corrected radiomics model could facilitate noninvasive preselection of ESCC patients who would benefit from ICI + CT.

27 April 2018 in Cancer Communications
Verified
Journal Article
Open access
PDF file
WYWang Yao
Wang Yao
YMYuqi Meng
Yuqi Meng
MLMingjian Lu
Mingjian Lu
WFWenzhe Fan
Wenzhe Fan
JHJinhua Huang
Jinhua Huang
ZZZhihua Zhu
Zhihua Zhu
Background: The association between type 2 diabetes mellitus (T2DM) and the risk of esophageal cancer remains unclear. The present study aimed to evaluate the impact of T2DM on short‐term outcomes and long‐term survival in patients with esophageal squamous cell cancer (ESCC). Methods: The present retrospective study included 862 patients diagnosed with ESCC between January 2001 and December 2010. Among them, 280 patients had T2DM. A 1:1 propensity score‐matched cohort consisting of 280 patients with and 280 without T2DM was selected from the 862 patients. The associations between T2DM and clinicopathologic characteristics were assessed using the χ 2 or Fisher's exact test. Survival of ESCC patients with and without T2DM was calculated by using the Kaplan–Meier method and compared by using the Cox regression model between the two groups. Results: The occurrence rate of anastomotic leakage was significantly higher in patients with T2DM than in those without T2DM ( P < 0.001). In the subgroup with weight loss rate ≤ 5.05%, ESCC patients with T2DM had a significant longer overall survival than did those without T2DM ( P = 0.003), whereas in the subgroup with weight loss rate > 5.05%, the patients without T2DM showed a longer survival ( P = 0.001). Univariate and multivariate analysis results showed that T2DM was not an independent prognostic factor for patient survival. Conclusions: Type 2 diabetes mellitus is not an independent prognostic factor in patients with ESCC. However, the combination of T2DM with severe weight loss would be a predictor of poor prognosis.

27 June 2012 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
QXQing Xia
Qing Xia
ZZZhihua Zhu
Zhihua Zhu
JWJian Wang
Jian Wang
DSDongrong Situ
Dongrong Situ
NZNingning Zhou
Ningning Zhou
WJWenqi Jang
Wenqi Jang

23 June 2021 in Autoimmunity
Verified
Journal Article
Open access
ZWZhen Wang
Zhen Wang
HYHan Yang
Han Yang
RZRusi Zhang
Rusi Zhang
BLBin Luo
Bin Luo
BXBingchen Xu
Bingchen Xu
PLPeng Lin
Peng Lin
Oesophageal squamous cell carcinoma (ESCC) is a malignant tumour of the digestive system that is associated with high morbidity and mortality rates worldwide. With the increased use of immunotherap...

1 February 2014
Verified
Journal Article
Open access
HYHui Yu
Hui Yu
XHXiuying Huang
Xiuying Huang
ZZZhihua Zhu
Zhihua Zhu
YHYi Hu
Yi Hu
WOWei Ou
Wei Ou
NZNingning Zhou
Ningning Zhou
To evaluate the significance of combined detection of LunX mRNA, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), and cytokeratin 21-1 fragment (CYFRA21-1) in clinical diagnosis of lung carcinoma. Based on the quantitative RT-PCR and chemiluminescence immunoassay, the expression levels of LunX mRNA, CEA, NSE, and CYFRA21-1 in 113 patients with lung carcinoma (case group) and 30 healthy participants (control group) were detected. Meantime, the sensitivity, specificity, and accuracy of the combination detection were also explored. The positive rates of LunX mRNA in peripheral blood and CEA, NSE, and CYFRA21-1 in serum were significantly higher in case group than those in control group (χ2=17.295, 16.825, 19.148, and 17.450; P0.05). The positive rate of LunX mRNA in stage I + II, III, and IV had a significantly increasing tendency (χ2=10.565, 32.462, P<0.05). The positive rate of CYFRA21-1 was highest in squamous carcinoma (78.5%), the positive rate of NSE was highest in small cell carcinoma (86.7%), and the positive rate of CEA wag highest in lung adenocarcinoma (80.4%). The sensitivity and accuracy of the combination detection were 91.1% and 88.1%, respectively. The combined detection of LunX mRNA and tumor markers (TMs) including CEA, NSE, and CYFRA21-1 in peripheral blood is helpful to increase the diagnostic accuracy of lung cancer. Also, it can inform the pathological typing of lung carcinoma.

31 July 2023 in BMC Cancer
Verified
Journal Article
Open access
PDF file
WMWeijian Mei
Weijian Mei
WYWang Yao
Wang Yao
ZSZhengbo Song
Zhengbo Song
WJWenjie Jiao
Wenjie Jiao
LZLianxin Zhu
Lianxin Zhu
ZZZhihua Zhu
Zhihua Zhu
Background: Radical resection plus lymph node dissection is a common treatment for patients with T1-3N0M0 non-small cell lung cancer (NSCLC). Few models predicted the survival outcomes of these patients. This study aimed to developed a nomogram for predicting their overall survival (OS). Materials and methods: This study involved 3002 patients with T1-3N0M0 NSCLC after curative resection between January 1999 and October 2013. 1525 Patients from Sun Yat-sen University Cancer Center were randomly allocated to training cohort and internal validation cohort in a ratio of 7:3. 1477 patients from ten institutions were recruited as external validation cohort. A nomogram was constructed based on the training cohort and validated by internal and external validation cohort to predict the OS of these patients. The accuracy and practicability were tested by Harrell's C-indexes, calibration plots and decision curve analyses (DCA). Results: Age, sex, histological classification, pathological T stage, and HI standard were independent factors for OS and were included in our nomogram. The C-index of the nomogram for OS estimates were 0.671 (95% CI, 0.637–0.705),0.632 (95% CI, 0.581–0.683), and 0.645 (95% CI, 0.617–0.673) in the training cohorts, internal validation cohorts, and external validation cohort, respectively. The calibration plots and DCA for predictions of OS were in excellent agreement. An online version of the nomogram was built for convenient clinical practice. Conclusions: Our nomogram can predict the OS of patients with T1-3N0M0 NSCLC after curative resection. The online version of our nomogram offer opportunities for fast personalized risk stratification and prognosis prediction in clinical practice.